glp-1 for long covid Experimental peptides are being advertised COVID. But the evidence is trailing behind The GLP-1 Agonist Boom in

Y., Fatemi, A., Reiter, R

During the 2023-2024 fiscal year, Kentucky Medicaid paid out $251 million for GLP-1 medication to treat 76,195 people, according to Cabinet for Health and Family Services spokeswoman Kendra Steele

While each medication offers unique advantages in terms of efficacy, dosing frequency, and tolerability, the overarching goal remains the sameto improve patient outcomes by addressing the complex interplay between obesity and metabolic disorders

Or they may recommend alternative treatments

Comes with 10 vials of 1200mg

It ignores everything we know about the biology of appetite regulation, genetic predisposition, and the hormonal disruption that follows repeated dieting cycles